|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6900 EUR | +6.48% |
|
+23.88% | -55.08% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 11/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 59.71M | |
| 29.28x | 6.09x | -0.73x | 5.36x | 22.26x | 30.13x | 2.65% | 316B | |
| 24.88x | 2.1x | -12.8x | 3.38x | 11.92x | 20.05x | 1.6% | 73.28B | |
| 12.48x | 13.11x | 0.08x | 6.33x | 9.65x | 10.59x | - | 9.87B | |
| 15.86x | 1.37x | 0.77x | 1.99x | 6.75x | 8.15x | 2.85% | 8.15B | |
| 21.29x | 5.65x | 2.14x | 6.02x | 17.05x | 17.76x | -.--% | 4.38B | |
| 36.73x | 2.4x | -1.7x | 2.34x | 27.37x | 41.97x | 0.75% | 3.91B | |
| 31.1x | - | 0.2x | 5.92x | 16.92x | 27.42x | - | 3.62B | |
| -135.16x | - | 2.55x | - | - | - | -.--% | 2.51B | |
| 63x | - | -0.12x | - | - | - | - | 1.26B | |
| 14.06x | 0.81x | -0.82x | 1.03x | 7.49x | 25.6x | 4.4% | 1.02B | |
| -69x | 1.67x | 1.04x | - | - | - | - | 930M | |
| Average | 4.05x | 4.15x | -0.85x | 4.05x | 14.93x | 22.71x | 1.75% | 35.43B | |
| Weighted average by Cap. | 26.75x | 5.40x | -2.71x | 4.94x | 19.77x | 27.44x | 2.41% |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
